Bath & Body Works (NYSE:BBWI) Issues Q1 Earnings Guidance

Bath & Body Works (NYSE:BBWI) updated its first quarter earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of $0.36-0.43 for the period, compared to the consensus estimate of $0.42. Bath & Body Works also updated its FY26 guidance to $3.25-360 EPS.

Bath & Body Works Trading Down 6.6 %

Shares of BBWI opened at $30.45 on Tuesday. The company has a market cap of $6.60 billion, a price-to-earnings ratio of 7.43, a P/E/G ratio of 0.92 and a beta of 1.89. The business’s fifty day simple moving average is $37.09 and its two-hundred day simple moving average is $34.14. Bath & Body Works has a 12 month low of $26.20 and a 12 month high of $52.99.

Bath & Body Works (NYSE:BBWI) last released its quarterly earnings data on Thursday, February 27th. The company reported $2.09 EPS for the quarter, beating the consensus estimate of $2.04 by $0.05. Bath & Body Works had a negative return on equity of 44.03% and a net margin of 12.43%. The company had revenue of $2.79 billion for the quarter, compared to analysts’ expectations of $2.78 billion. As a group, research analysts forecast that Bath & Body Works will post 3.3 EPS for the current year.

Bath & Body Works Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, March 7th. Stockholders of record on Friday, February 21st were issued a dividend of $0.20 per share. The ex-dividend date was Friday, February 21st. This represents a $0.80 annualized dividend and a dividend yield of 2.63%. Bath & Body Works’s payout ratio is 21.98%.

Bath & Body Works announced that its board has approved a share repurchase program on Thursday, February 27th that authorizes the company to repurchase $500.00 million in shares. This repurchase authorization authorizes the company to buy up to 6.4% of its shares through open market purchases. Shares repurchase programs are generally an indication that the company’s management believes its stock is undervalued.

Analyst Ratings Changes

A number of research analysts have weighed in on the company. Cowen reissued a “buy” rating on shares of Bath & Body Works in a report on Thursday, February 27th. Robert W. Baird upped their price target on shares of Bath & Body Works from $45.00 to $47.00 and gave the company an “outperform” rating in a research report on Friday, February 28th. Wells Fargo & Company raised shares of Bath & Body Works from an “equal weight” rating to an “overweight” rating and raised their price objective for the stock from $42.00 to $48.00 in a report on Friday, January 10th. Telsey Advisory Group restated an “outperform” rating and set a $43.00 target price on shares of Bath & Body Works in a research report on Thursday, February 27th. Finally, Deutsche Bank Aktiengesellschaft increased their price target on shares of Bath & Body Works from $51.00 to $52.00 and gave the stock a “buy” rating in a research report on Tuesday, November 26th. Five equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $45.06.

Bath & Body Works Company Profile

Bath & Body Works, Inc is a specialty retailers and home to America’s Favorite Fragrances, offering a breadth of exclusive fragrances for the body and home, including the selling collections for fine fragrance mist, body lotion and body cream, 3-wick candles, home fragrance diffusers and liquid hand soap.